Ibrutinib-related atrial fibrillation in patients with mantle cell lymphoma

Leukemia and Lymphoma

Volumn 57, Issue 12, 2016, Pages 2914-2916

  Lee, Hun Ju ^a   Chihara, Dai ^a   Wang, Michael ^a   Mouhayar, Elie ^a   Kim, Peter ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; DABIGATRAN; DILTIAZEM; FLECAINIDE; IBRUTINIB; LOW MOLECULAR WEIGHT HEPARIN; RITUXIMAB; WARFARIN; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANTICOAGULANT THERAPY; ATRIAL FIBRILLATION; CANCER RECURRENCE; CARDIOVASCULAR RISK; CARDIOVERSION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; HEART PALPITATION; HUMAN; HYPERTENSION; LETTER; MANTLE CELL LYMPHOMA; PACEMAKER IMPLANTATION; PRIORITY JOURNAL; SEPSIS; SINUS RHYTHM; STEM CELL TRANSPLANTATION; TACHYCARDIA; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK; AGED; CHEMICALLY INDUCED; FEMALE; FOLLOW UP; INCIDENCE; MALE; RECURRENT DISEASE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LYMPHOMA, MANTLE-CELL; MALE; PYRAZOLES; PYRIMIDINES; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84963805026     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2016.1169408     Document Type: Letter

References (11)

1. M.L.Wang, K.A.Blum, P.Martin,. Long-term follow-up of MCL patients treated with single-agent ibrutinib:updated safety and efficacy results. Blood. 2015;126:739–745.
2. J.A.Burger, M.J.Keating, W.G.Wierda,. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia:a single-arm, phase 2 study. Lancet Oncol. 2014;15:1090–1099.
3. J.C.Byrd, R.R.Furman, S.E.Coutre,. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125:2497–2506.
4. M.Z.Farooqui, J.Valdez, S.Martyr,. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations:a phase 2, single-arm trial. Lancet Oncol. 2015;16:169–176.
5. S.O’Brien, R.R.Furman, S.E.Coutre,. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma:an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014;15:48–58.
6. S.P.Treon, C.K.Tripsas, K.Meid,. Ibrutinib in previously treated Waldenström’s macroglobulinemia. N Engl J Med. 2015;372:1430–1440.
7. J.C.Byrd, J.R.Brown, S.O’Brien,. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213–223.
8. J.C.Byrd, R.R.Furman, S.E.Coutre,. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42.
9. Y.Wang, L.L.Zhang, R.E.Champlin,. Targeting Bruton’s tyrosine kinase with ibrutinib in B-cell malignancies. Clin Pharmacol Therap. 2015;97:455–468.
10. J.Fine, R.J.Gray A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509.
11. J.R.McMullen, E.J.Boey, J.Y.Ooi,. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood. 2014;124:3829–3830.